Company
Headquarters: Los Angeles, CA, United States
Employees: 3
$19.8 Million
USD as of Oct. 1, 2021
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Vitality Biopharma, Inc. focuses on developing cannabinoid pharmaceutical prodrugs in the United States. The company produces approximately 25 novel cannabosides, including glycosylated tetrahydrocannabinol (THC), cannabidiol, cannabidivarin, and cannabinol. It is developing THC-glycoside (VBX-100), an oral prodrug for the treatment of gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was incorporated in 2007 and is headquartered in Los Angeles, California.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Vitality Biopharma, Inc. has the following listings and related stock indices.
Stock: OTC: VBIO wb_incandescent